XSDR:LSE:LSE-Xtrackers MSCI Europe Health Care ESG Screened UCITS ETF 1C (GBX)

ETF | Others |

Last Closing

USD 17632

Change

0.00 (0.00)%

Market Cap

USD 0.21B

Volume

712.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-06-01 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
0R1O:LSE Amazon.com Inc.

+1.10 (+0.53%)

USD 1,607.29B
LCJP:LSE Lyxor Core MSCI Japan (DR) UCI..

-0.04 (-0.30%)

USD 640.06B
LCJD:LSE Amundi MSCI Japan (DR) UCITS E..

-0.10 (-0.52%)

USD 640.06B
0R1I:LSE NVIDIA Corp.

+4.93 (+3.62%)

USD 618.20B
0R1G:LSE Home Depot Inc.

+6.86 (+1.88%)

USD 373.16B
PRJU:LSE Amundi Index Solutions - Amund..

-0.16 (-0.49%)

USD 269.13B
0QZK:LSE Coca-Cola Co.

-0.62 (-0.86%)

USD 266.08B
0QZO:LSE 0QZO

+1.31 (+1.17%)

USD 258.54B
0QZ3:LSE Qualcomm Inc.

+4.60 (+3.19%)

USD 202.26B
0R24:LSE Intel Corp.

+0.52 (+2.61%)

USD 196.14B

ETFs Containing XSDR:LSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -1.40% 34% F 39% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -1.40% 33% F 38% F
Trailing 12 Months  
Capital Gain -11.65% 9% A- 24% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -11.65% 9% A- 23% F
Trailing 5 Years  
Capital Gain 19.95% 35% F 46% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 19.95% 31% F 43% F
Average Annual (5 Year Horizon)  
Capital Gain 7.71% 53% F 61% D-
Dividend Return 7.71% 52% F 60% D-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 7.31% 78% C+ 89% A-
Risk Adjusted Return 105.42% 91% A- 95% A
Market Capitalization 0.21B 61% D- 35% F

Annual Financials (GBX)

Quarterly Financials (GBX)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:

There is nothing we particularly dislike